Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs

Area of Science:

• Neonatal Pharmacology
• Drug Development
• Pediatric Medicine

Background:

• Neonatal drug dosing necessitates a comprehensive approach, considering the specific disease, infant physiology, and drug pharmacokinetics (PK) and pharmacodynamics (PD).
• Diverse data sources, including adult, pediatric, non-clinical, in vitro, and in silico models, are vital for optimizing neonatal dose selection.

Purpose of the Study:

• To illustrate the variability in drug development programs for neonatal diseases.
• To examine approaches for diseases similar to, related to, or unique to the neonatal population.

Main Methods:

• Review of drug development programs for various neonatal conditions.
• Analysis of data extrapolation strategies from other populations to neonates.
• Consideration of maturational PK and body size in neonatal dosing.

Main Results:

• Extrapolation of efficacy from adults or older children to neonates is rarely employed.
• Dosing for neonatal diseases requires specific data, even when disease processes resemble those in other age groups.
• Neonatal dosing is complicated by maturational PK and body size variations.

Conclusions:

• Integrated knowledge of disease, neonate physiology, and drug PK/PD is essential for neonatal drug dosing.
• A multi-modal data approach is critical for optimizing neonatal medication regimens.
• Specific dosing and safety data are indispensable for neonatal drug labeling.